Search
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigational[A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products. … It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676].
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigationalSuccinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups.
Imipramine
go.drugbank.com/drugs/DB00458ApprovedInvestigationalIn non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood.
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedMore specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. … [L5744] In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Lansoprazole
go.drugbank.com/drugs/DB00448ApprovedInvestigationalalong with other pathologies caused by excessive acid secretion. … [A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD)
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawn[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[L1118] It was never approved by the FDA.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnBoceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigationalIn May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL. … [L49464] In November 2025, epcoritamab in combination with rituximab and lenalidomide was approved by the FDA for adult patients with relapsed or refractory follicular lymphoma.[L54713]